Syapse

Canaccord Genuity Advises Syapse on its Acquisition by N-Power Medicine to Expand its Next-Generation Community-Based Network for Oncology Clinical Research and Clinical Trials

This transaction accelerates scale-up of N-Power’s unique “always-on” prospective clinical research model, adding an extensive network of community health systems and 1,000+ community oncologists across the U.S.

Canaccord Genuity has advised Syapse Holdings, Inc. (Syapse), a pioneer in precision medicine solutions for community cancer centers, on its acquisition by N-Power Medicine, a company leading the reinvention of the clinical trial process. 

Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care. By marrying clinical expertise with smart technologies, Syapse transforms data into evidence – and then into experience – in collaboration with its network of partners, who are committed to improving patients’ lives through community health systems. Syapse connects comprehensive patient insights to its network to empower its partners in driving real impact and improving access to high-quality care.

N-Power Medicine is a clinical research and drug development platform company that aims to dramatically boost clinical trial participation to accelerate oncology drug development – and deliver on the promise of bringing life-saving innovation to cancer patients. Founded in 2021, the company addresses critical challenges for oncology sites by integrating technology and trained personnel into routine care to unlock the full potential of the data needed to bring new therapies to patients sooner.

N-Power partners with community oncologists through its proprietary real-time Kaleido Registry and AI-powered point-of-care platform, complemented by virtual and on-site support, to optimize research and patient care workflows. Through the acquisition, N-Power Medicine will integrate Syapse’s extensive network of community-based health systems, with more than 1,000 oncologists, its data and technology stack, and its dedicated team. This expansion of the N-Power network will address critical gaps in patient access to clinical trials in the community setting, where more than 80% of U.S. cancer patients—particularly those from diverse and underrepresented populations—receive their care. 

The transaction will enhance N-Power’s current offerings to its pharmaceutical customers with significantly greater access to more representative, geographically diverse, and community-based cancer patients for enrollment in clinical trials. It will also enable rapid and rigorous generation of prospective external controls, allowing for much smaller and faster clinical trials. 

The integration of Syapse into N-Power represents a transformative step forward in the shared mission to revolutionize community-based patient care. By building upon Syapse’s existing offerings and foundational data platform with N-Power’s AI-enabled ‘human-in-the-loop’ approach, the combined company can significantly expand access to prospective clinical trials and life-saving innovations for patients in community settings.

N-Power’s acquisition of Syapse was completed as a stock-for-stock exchange on Dec. 30, 2024. Innovatus Capital Partners LLC, Syapse’s lead institutional investor, joins N-Power’s existing investors, including the Merck Global Health Innovation Fund (GHI) and a U.S. based healthcare-focused investor, in providing ongoing funding for N-Power’s vision.